Search

Your search keyword '"Kim, Soon Sun"' showing total 248 results
Start Over Author "Kim, Soon Sun" Search Limiters Full Text
248 results on '"Kim, Soon Sun"'

14. Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib

Author

Cho, Hyo Jung, Kim, Soon Sun, Nam, Ji Sun, Oh, Min Jung, Kang, Dae Ryong, Kim, Jai Keun, Lee, Jei Hee, Kim, Bohyun, Yang, Min Jae, Hwang, Jae Chul, Lim, Sun Gyo, Shin, Sung Jae, Lee, Kee Myung, Yoo, Byung Moo, Lee, Kwang Jae, Cho, Sung Won, and Cheong, Jae Youn

Published
2017
Full Text
View/download PDF

19. Regular Alpha-Fetoprotein Tests Boost Curative Treatment and Survival for Hepatocellular Carcinoma Patients in an Endemic Area.

Author

Oh, Joo Hyun, Lee, Jonghyun, Yoon, Eileen L., Jeong, Soung Won, Kim, Soon Sun, Chon, Young Eun, Ahn, Sang Bong, and Jun, Dae Won

Subjects
ALPHA fetoproteins, DISEASE clusters, EVALUATION of medical care, CAUSES of death, CONFIDENCE intervals, MULTIVARIATE analysis, MEDICAL screening, CANCER patients, DESCRIPTIVE statistics, RESEARCH funding, HEPATOCELLULAR carcinoma, CHRONIC hepatitis B
Abstract

Simple Summary: This study evaluated the impact of alpha-fetoprotein (AFP) testing frequency on survival rates in hepatocellular carcinoma (HCC) patients. Analyzing data from 81,520 patients in Korea, it was found that increased AFP testing significantly improved survival, particularly in patients with hepatitis B undergoing antiviral treatment. Those tested three or more times before diagnosis had a higher likelihood of receiving curative treatments, such as liver transplantation. The study suggests that combining AFP tests with ultrasound screenings could better detect HCC early, offering enhanced treatment opportunities and improved survival chances, especially for hepatitis B patients. Guidelines vary on alpha-fetoprotein (AFP) testing for hepatocellular carcinoma (HCC) screening. This study aims to reassess AFP's role in HCC surveillance, utilizing a comprehensive, recent, nationwide cohort. Utilizing the National Health Claims Database from the Korean National Health Insurance Service, this research included data from 185,316 HCC patients registered between 2008 and 2018. Specifically, 81,520 patients diagnosed with HCC from 2008 to 2014 were analyzed. The study focused primarily on mortality and, secondarily, on the status of curative treatments. Multivariate analysis revealed that frequent AFP testing significantly impacts overall survival in HCC patients. Specifically, each additional AFP test correlated with a 6% relative improvement in survival (hazard ratio = 0.94, 95% CI: 0.940–0.947, p < 0.001). Patients who underwent AFP testing three or more times within two years prior to HCC diagnosis showed improved survival rates, with 55.6% receiving liver transplantation or hepatectomy. This trend was particularly pronounced in hepatitis B patients undergoing antiviral treatment. The findings highlight the potential of regular AFP testing to enhance survival in HCC patients, especially those with hepatitis B. Integrating frequent AFP testing with ultrasonography could increase the likelihood of early detection and access to curative treatments. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Consensus Definition of Blood Samples from the Subcategorized Normal Controls in the Korea Biobank Network

Author

Han, Ji Eun, primary, Park, Min Kyu, additional, Jin, Ju Hyun, additional, Lee, Jung Ah, additional, Park, Gyeongsin, additional, Park, Jong Sook, additional, Bae, Han-Ik, additional, Yun, Seok Joong, additional, Seo, An Na, additional, Han, Man-Hoon, additional, Lee, Hyoungnam, additional, Jeon, Jae-Pil, additional, Yu, Ji-In, additional, Kim, Soon Sun, additional, and Cheong, Jae Youn, additional

Published
2023
Full Text
View/download PDF

23. Current status of ultrasonography in national cancer surveillance program for hepatocellular carcinoma in South Korea: a large-scale multicenter study

Author

Yoo, Sun Hong, primary, Kim, Soon Sun, additional, Kim, Sang Gyune, additional, Kwon, Jung Hyun, additional, Lee, Han-Ah, additional, Seo, Yeon Seok, additional, Jung, Young Kul, additional, Yim, Hyung Joon, additional, Song, Do Seon, additional, Kang, Seong Hee, additional, Kim, Moon Young, additional, Ahn, Young-Hwan, additional, Han, Jieun, additional, Kim, Young Seok, additional, Chang, Young, additional, Jeong, Soung Won, additional, Jang, Jae Young, additional, and Yoo, Jeong-Ju, additional

Published
2023
Full Text
View/download PDF

24. Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib

Author

Eun, Jung Woo, primary, Yoon, Jung Hwan, additional, Ahn, Hye Ri, additional, Kim, Seokhwi, additional, Kim, Young Bae, additional, Lim, Su Bin, additional, Park, Won, additional, Kang, Tae Wook, additional, Baek, Geum Ok, additional, Yoon, Moon Gyeong, additional, Son, Ju A, additional, Weon, Ji Hyang, additional, Kim, Soon Sun, additional, Cho, Hyo Jung, additional, and Cheong, Jae Youn, additional

Published
2023
Full Text
View/download PDF

25. Aberrantly Expressed MicroRNAs in Cancer-Associated Fibroblasts and Their Target Oncogenic Signatures in Hepatocellular Carcinoma

Author

Eun, Jung Woo, primary, Ahn, Hye Ri, additional, Baek, Geum Ok, additional, Yoon, Moon Gyeong, additional, Son, Ju A, additional, Weon, Ji Hyang, additional, Yoon, Jung Hwan, additional, Kim, Hyung Seok, additional, Han, Ji Eun, additional, Kim, Soon Sun, additional, Cheong, Jae Youn, additional, Kim, Bong-wan, additional, and Cho, Hyo Jung, additional

Published
2023
Full Text
View/download PDF

33. Additional file 1 of Hypomethylation-mediated upregulation of the WASF2 promoter region correlates with poor clinical outcomes in hepatocellular carcinoma

Author

Ahn, Hye Ri, Baek, Geum Ok, Yoon, Moon Gyeong, Son, Ju A, Yoon, Jung Hwan, Cheong, Jae Youn, Cho, Hyo Jung, Kang, Ho Chul, Eun, Jung Woo, and Kim, Soon Sun

Abstract

Additional file 1: Table S1. Demographics and clinical characteristics of patients. Table S2. Primer sequences. Table S3. Primary antibodies. Table S4. Secondary antibodies. Table S5. ROC results of 47 autoantibodies. Table S6. Univariate and multivariate Cox regression analyses of factors associated with overall survival. Table S7. Univariate and multivariate Cox regression analyses of factors associated with progression-free survival. Table S8. Univariate and multivariate Cox regression analyses of factors associated with disease-free survival. Table S9. Univariate and multivariate Cox regression analyses of factors associated with disease-specific survival.

Published
2022
Full Text
View/download PDF

34. Additional file 2 of Hypomethylation-mediated upregulation of the WASF2 promoter region correlates with poor clinical outcomes in hepatocellular carcinoma

Author

Ahn, Hye Ri, Baek, Geum Ok, Yoon, Moon Gyeong, Son, Ju A, Yoon, Jung Hwan, Cheong, Jae Youn, Cho, Hyo Jung, Kang, Ho Chul, Eun, Jung Woo, and Kim, Soon Sun

Abstract

Additional file 2: Fig. S1. A WASF2 expression in matched pairs of patients with HCC from TCGA_LIHC, ICGC_LIRI, and GSE77314 datasets. B Differential expression of WASF2 in human hepatocarcinogenesis in GSE6764, GSE12443, and GSE114564 datasets (one-way ANOVA, post hoc comparisons, Tukey’s test). C Representative images of WASF2 expression in HCC tissues and D proportion of patients with different WASF2 immunostaining intensity in HCC specimens based on Human Protein Atlas (HPA) data. Scale bar = 200 μm. E Kaplan–Meier survival analyses of WASF2 expression in TCGA_LIHC datasets for overall survival (left), disease-specific survival (middle), and progression-free survival (right; log-rank test *P 0.3 or r

Published
2022
Full Text
View/download PDF

35. Risk Prediction Model Based on Magnetic Resonance Elastography-Assessed Liver Stiffness for Predicting Posthepatectomy Liver Failure in Patients with Hepatocellular Carcinoma

Author

Cho, Hyo Jung, primary, Ahn, Young Hwan, additional, Sim, Min Suh, additional, Eun, Jung Woo, additional, Kim, Soon Sun, additional, Kim, Bong Wan, additional, Huh, Jimi, additional, Lee, Jei Hee, additional, Kim, Jai Keun, additional, Lee, Buil, additional, Cheong, Jae Youn, additional, and Kim, Bohyun, additional

Published
2022
Full Text
View/download PDF

41. Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C

Author

Ahn, Young-Hwan, primary, Lee, Heirim, additional, Kim, Do Young, additional, Lee, Hye Won, additional, Yu, Su Jong, additional, Cho, Young Youn, additional, Jang, Jeong Won, additional, Jang, Byoung Kuk, additional, Kim, Chang Wook, additional, Kim, Hee Yeon, additional, Park, Hana, additional, Cho, Hyo Jung, additional, Park, Bumhee, additional, Kim, Soon Sun, additional, and Cheong, Jae Youn, additional

Published
2021
Full Text
View/download PDF

44. Bioelectrical impedance analysis for predicting postoperative complications and survival after liver resection for hepatocellular carcinoma

Author

Lee, Gil Ho, primary, Cho, Hyo Jung, additional, Lee, Garam, additional, Kim, Han Gyeol, additional, Wang, Hee Jung, additional, Kim, Bong-Wan, additional, Lee, Mi Young, additional, Yoon, So Young, additional, Noh, Choong-Kyun, additional, Seo, Chul Won, additional, Eun, Jung Woo, additional, Cheong, Jae Youn, additional, Cho, Sung Won, additional, and Kim, Soon Sun, additional

Published
2021
Full Text
View/download PDF

49. Exosomal microRNA‐4661‐5p–based serum panel as a potential diagnostic biomarker for early‐stage hepatocellular carcinoma

Author

Cho, Hyo Jung, primary, Baek, Geum Ok, additional, Seo, Chul Won, additional, Ahn, Hye Ri, additional, Sung, Suna, additional, Son, Ju A, additional, Kim, Soon Sun, additional, Cho, Sung Won, additional, Jang, Jeong Won, additional, Nam, Suk Woo, additional, Cheong, Jae Youn, additional, and Eun, Jung Woo, additional

Published
2020
Full Text
View/download PDF

50. Endoscopic large-balloon dilation alone versus endoscopic sphincterotomy plus large-balloon dilation for the treatment of large bile duct stones

Author

Hwang Jae Chul, Kim Jin Hong, Lim Sun Gyo, Kim Soon Sun, Shin Sung Jae, Lee Kee Myung, and Yoo Byung Moo

Subjects
Common bile duct stones, Endoscopic sphincterotomy, Large-balloon dilation, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Abstract Background Endoscopic sphincterotomy (EST) combined with large-balloon dilation (LBD) has been proposed as an alternative to manage large bile duct stones. However, recent reports indicate that LBD without EST may be safe and effective in this setting. Methods One hundred thirty-one patients with large common bile duct (CBD) stones 12 mm in size or larger underwent LBD alone (n = 62) or EST plus LBD (n = 69) for lithotripsy. The therapeutic outcome and complications were reviewed and compared. Results There were no differences between the two groups with regard to age, size and number of stones, or bile duct diameter. The LBD alone group (mean age, 70.4 years) and the EST plus LBD group (mean age, 68.2 years) had similar outcomes in terms of overall successful stone removal (96.8% vs. 95.7%, P = 0.738) and complete stone removal without the need for mechanical lithotripsy (80.6% vs. 73.9%, P = 0.360). Complications in the LBD alone and EST plus LBD groups were as follows: pancreatitis (6.5% vs. 4.3%, P = 0.593), impaction of basket and stone (0% vs. 1.4%, P = 0.341), and perforation (0% vs. 1.4%, P = 0.341). Conclusions LBD alone may be a simple, safe, and effective alternative to EST plus LBD in relatively aged patients with large CBD stones, and it can simplify the procedure compared with EST plus LBD.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results